Digoxin-specific antibodies: a novel dosing strategy

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Digoxin-specific antibodies (digoxin-Fabs) are of value in the treatment of a strongly suspected or a known, potentially life-threatening digoxin toxicity. These antibodies are not registered for use in Europe; therefore Dutch hospital pharmacies are not allowed to keep them in stock. In the Netherlands, digoxin-Fabs are stored in a national calamity stock of emergency medicines at the National Institute for Public Health and the Environment. In the case of a medical emergency, digoxin-Fabs are available after contact with the Dutch Poisons Information Centre. Recent studies have shown that the dose of digoxin-Fabs required to effectively treat digoxin toxicity is lower than previously thought. In this article, we present the adjusted digoxin-Fab dosing strategy currently recommended by the Dutch Poisons Information Centre (www.vergiftigingen.info). This new dose titration strategy is safe and effective and has a cost-saving side-effect.

Cite

CITATION STYLE

APA

Dijkman, M. A., Gresnigt, F. M. J., & de Lange, D. W. (2024). Digoxin-specific antibodies: a novel dosing strategy. Netherlands Heart Journal, 32(2), 70–73. https://doi.org/10.1007/s12471-023-01814-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free